Lysa
19 June 2018
LYSA’s RELEVANCE Trial in the Media
Return on the presentation of Franck Morschhauser, from Claude Huriez Hospital (Lille, France), president of the LYSA scientific committee, on the interim results obtained for the phase III clinical trial RELEVANCE.
Please, discover the press release on this study, published on the website of ASHand the video made by ecancer!
Reference: Franck Morschhauser et al. Relevance : Phase III Efficacity and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma.
News
08 February 2024 Lysa
Le LYSA s’enrichit d’une commission en ch...
02 December 2022 Lysa
LYSA at ASH 2022
The 64th ASH Annual Meeting and Exposition will be held December 10-13, 202...
19 October 2022 Lysa
Launch of the TRANSCRIPT study
The objective of the TRANSCRIPT study is to know if autotransplantation red...